A surface on the androgen receptor that allosterically regulates coactivator binding
暂无分享,去创建一个
Phuong Nguyen | Eva Estébanez-Perpiñá | R Kiplin Guy | Paul Webb | Kevan M Shokat | R. Fletterick | K. Shokat | R. Guy | J. Baxter | P. Webb | P. Pallai | L. Arnold | E. Estébanez-Perpiñá | Ellena Mar | P. Nguyen | Robert J Fletterick | R. Bateman | Leggy A Arnold | John D Baxter | Edson Delgado Rodrigues | Ellena Mar | Raynard Bateman | Peter Pallai | E. Estébanez‐Perpiñá | E. Rodrigues
[1] F. Larrea,et al. Novel molecular defects in the androgen receptor gene of Mexican patients with androgen insensitivity , 2001, Clinical genetics.
[2] N. Chirgadze,et al. A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[3] Grazia Chiellini,et al. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[4] Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. , 2001, Molecular endocrinology.
[5] V. Jordan,et al. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). , 2005, Breast disease.
[6] D. Chen,et al. Identification of amino acids in the tau 2-region of the mouse glucocorticoid receptor that contribute to hormone binding and transcriptional activation. , 1997, Molecular endocrinology.
[7] R. Fletterick,et al. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. , 2002, Endocrinology.
[8] D. McDonnell,et al. Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. , 2005, Molecular endocrinology.
[9] R. Flower. The development of COX2 inhibitors , 2003, Nature Reviews Drug Discovery.
[10] R. Fletterick,et al. A High-Throughput Screening Method to Identify Small Molecule Inhibitors of Thyroid Hormone Receptor Coactivator Binding , 2006, Science's STKE.
[11] D. McDonnell,et al. Androgen receptor-cofactor interactions as targets for new drug discovery. , 2005, Trends in pharmacological sciences.
[12] J. Katzenellenbogen,et al. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor α coactivator binding , 2004 .
[13] R. Fletterick,et al. Discovery of Small Molecule Inhibitors of the Interaction of the Thyroid Hormone Receptor with Transcriptional Coregulators* , 2005, Journal of Biological Chemistry.
[14] B. O’Malley,et al. The Expanding Cosmos of Nuclear Receptor Coactivators , 2006, Cell.
[15] Bin He,et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. , 2004, Molecular cell.
[16] P B Sigler,et al. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[17] P. Toogood. Progress toward the development of agents to modulate the cell cycle. , 2002, Current opinion in chemical biology.
[18] Vicki L. Nienaber,et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.
[19] H. Scher,et al. Collocation of androgen receptor gene mutations in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[21] R J Fletterick,et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. , 1998, Science.
[22] C. Glass,et al. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. , 2006, Genes & development.
[23] M. McPhaul. Androgen receptor mutations and androgen insensitivity , 2002, Molecular and Cellular Endocrinology.
[24] F. Ghadessy,et al. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2). , 2000, Molecular endocrinology.
[25] T. Berg. Modulation of protein-protein interactions with small organic molecules. , 2003, Angewandte Chemie.
[26] N. Mitro,et al. The nuclear receptor LXR is a glucose sensor , 2007, Nature.
[27] E. Wilson,et al. The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. , 2002, Molecular genetics and metabolism.
[28] Drug discovery at signaling interfaces. , 2003, Ernst Schering Research Foundation workshop.
[29] Liang Xia,et al. Functional analysis of 44 mutant androgen receptors from human prostate cancer. , 2002, Cancer research.
[30] Olivier Poch,et al. Signature of the oligomeric behaviour of nuclear receptors at the sequence and structural level , 2004, EMBO reports.
[31] B. Darimont. Finding specificity within a conserved interaction site. , 2003, Chemistry & biology.
[32] D. Djakiew,et al. Dihydrotestosterone (DHT) modulates the ability of NSAIDs to induce apoptosis of prostate cancer cells , 2002, Cancer Chemotherapy and Pharmacology.
[33] Vincent Laudet,et al. The nuclear receptor factsbook , 2002 .
[34] R. Fletterick,et al. The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor* , 2005, Journal of Biological Chemistry.
[35] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] D. Tindall,et al. Molecular regulation of androgen action in prostate cancer , 2006, Journal of cellular biochemistry.
[37] Hanne Grøn,et al. Recognition and Accommodation at the Androgen Receptor Coactivator Binding Interface , 2004, PLoS biology.
[38] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[39] Kendall W Nettles,et al. Ligand control of coregulator recruitment to nuclear receptors. , 2005, Annual review of physiology.
[40] C. Heinlein,et al. Androgen receptor in prostate cancer. , 2004, Endocrine reviews.